Intellia Therapeutics Inc (NASDAQ: NTLA) kicked off on Monday, up 3.57% from the previous trading day, before settling in for the closing price of $12.62. Over the past 52 weeks, NTLA has traded in a range of $5.90-$28.25.
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -20.04%. While this was happening, its average annual earnings per share was recorded 21.30%. With a float of $101.56 million, this company’s outstanding shares have now reached $105.33 million.
Considering the fact that the conglomerate employs 403 people, you should pay attention to its efficiency factor.
Intellia Therapeutics Inc (NTLA) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Intellia Therapeutics Inc is 5.39%, while institutional ownership is 90.39%. The most recent insider transaction that took place on Oct 01 ’25, was worth 539. In this transaction EVP, Chief Scientific Officer of this company sold 31 shares at a rate of $17.38, taking the stock ownership to the 105,184 shares. Before that another transaction happened on Oct 01 ’25, when Company’s VP, Chief Accounting Officer sold 1,871 for $17.38, making the entire transaction worth $32,518. This insider now owns 55,266 shares in total.
Intellia Therapeutics Inc (NTLA) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -1.34 earnings per share (EPS), higher than consensus estimate (set at -1.37) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.95 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 21.30% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 25.89% during the next five years compared to -20.04% drop over the previous five years of trading.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
Take a look at Intellia Therapeutics Inc’s (NTLA) current performance indicators. Last quarter, stock had a quick ratio of 5.19. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 26.54.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.69, a number that is poised to hit -1.01 in the next quarter and is forecasted to reach -3.82 in one year’s time.
Technical Analysis of Intellia Therapeutics Inc (NTLA)
Compared to the last year’s volume of 4.99 million, its volume of 14.25 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 6.45%.
During the past 100 days, Intellia Therapeutics Inc’s (NTLA) raw stochastic average was set at 25.04%, which indicates a significant increase from 8.66% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.75 in the past 14 days, which was higher than the 1.09 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.15, while its 200-day Moving Average is $11.51. Nevertheless, the first resistance level for the watch stands at $13.71 in the near term. At $14.36, the stock is likely to face the second major resistance level. The third major resistance level sits at $15.11. If the price goes on to break the first support level at $12.31, it is likely to go to the next support level at $11.56. Should the price break the second support level, the third support level stands at $10.91.
Intellia Therapeutics Inc (NASDAQ: NTLA) Key Stats
The company with the Market Capitalisation of 1.40 billion has total of 107,347K Shares Outstanding. Its annual sales at the moment are 57,880 K in contrast with the sum of -519,020 K annual income. Company’s last quarter sales were recorded 14,250 K and last quarter income was -101,260 K.
